Partnerships
Innovating together for better outcomes
As part of our work to realize the full potential of our therapeutic platform, we are proud to partner with some of the world’s leading scientific innovators.
Our partnered programs
Partnering with Takeda to advance CNP-101/TAK-101
With COUR’s expertise in inflammatory diseases, Takeda is well positioned to further develop CNP-101/TAK-101 in pursuit of providing the first approved treatment option for patients with celiac disease, a multibillion-dollar market.
Partnering with Genentech to advance a tolerogenic therapy for the treatment of an autoimmune disease
COUR has established a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease. COUR is responsible for the preclinical development and technical transfer of manufacturing. Genentech will be responsible for clinical development, regulatory filing, and commercialization.
Partner with us
We seek strategic partners interested in leveraging our proprietary platform technology to explore noncore indications, expand our therapeutic reach, and accelerate company growth and capabilities.
To learn more about partnering with us, please email BD@courpharma.com